Observational studyOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Baseline serum PINP is associated with early lumbar spine bone mineral density gains during twice-weekly teriparatide treatment: the OASIS cohort study.
Observational study in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baseline serum PINP was significantly and independently associated with achieving a ≥ 8% increase in lumbar spine (LS) bone mineral density (BMD) after 12 months of twice-weekly teriparatide therapy. PURPOSE: Early predictors of the BMD response to twice-weekly teriparatide remain poorly defined. This study aimed to identify clinical and biochemical determinants of early LS BMD improvement under this regimen.
methodIn this retrospective multicenter cohort study, 242 osteoporosis patients at high fracture risk completed 12 months of twice-weekly teriparatide (28.2 μg). At baseline, 88.0% were female, mean age was 80.0 years, 83.5% had a history of osteoporotic fracture, and 72.3% were treatment-naïve. Multivariate regression was performed to identify independent predictors of LS BMD change, and receiver operating characteristic (ROC) analysis was used to determine the optimal cutoff value for predicting an LS BMD increase ≥ 8% at 12 months.
resultsThe percent change (mean ± standard deviation) in LS BMD was 7.0 ± 8.6%, and 41.3% of patients achieved an LS BMD increase ≥ 8% at 12 months. In the multivariate model, baseline total procollagen type I N-terminal propeptide (PINP) was significantly and independently associated with percent LS BMD change (standardized coefficient = 2.73, p < 0.001). ROC analysis identified a baseline PINP cutoff of 53.1 μg/L for predicting ≥ 8% LS BMD increase (sensitivity 74.4%, specificity 60.5%, area under the curve = 0.67).
conclusionBaseline serum PINP represents one of the clinically relevant independent predictors of early LS BMD response to twice-weekly teriparatide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.